Phase I/II study of weekly oraxol for the second-line treatment of patients with metastatic or recurrent gastric cancer

Oncologist

Volumn 20, Issue 8, 2015, Pages 896-897

  Lee, Keun Wook ^a,b   Lee, Kyung Hee ^c   Zang, Dae Young ^d   Park, Young Iee ^e   Shin, Dong Bok ^f   Won Kim, Jin ^a,b   Im, Seock Ah ^b   Koh, Sung Ae ^c   Yu, Kyung Sang ^g   Cho, Joo Youn ^g   Jung, Jin A ^h   Bang, Yung Jue ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Young Nam University Hospital   (South Korea)

^d Hallym University   (South Korea)

^e National Cancer Center   (South Korea)

^f Gachon University   (South Korea)

^g Seoul National University Hospital   (South Korea)

^h Hanmi Pharmaceutical Co Ltd   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HM30181A; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAXIMUM TOLERATED DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; STOMACH CANCER; CLINICAL TRIAL; FEMALE; MALE; STOMACH NEOPLASMS; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; STOMACH NEOPLASMS;

EID: 84940037954     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0202     Document Type: Article

References (0)